Concurrent use of antiplatelet agents such as aspirin may increase the risk of bleeding. If combined therapy is medically necessary (e.g., after coronary stenting), the prescribing clinician will weigh the benefits against the bleeding risk and may adjust doses or monitor more closely.
Maintain the 12-hour interval between doses as closely as possible. If a dose is missed and the next scheduled dose is more than 8 hours away, take the missed tablet as soon as you remember, then continue with the regular schedule. Do not take two tablets at once.
Both contain the same active ingredient, apixaban, at identical strengths and are bioequivalent. Differences, if any, are limited to inactive ingredients or packaging, which generally do not affect clinical efficacy.
Patients with a history of gastrointestinal ulceration are at higher risk of bleeding. Eliquis may still be used, but the prescriber might choose a lower dose, add a gastro-protective agent, or prefer an alternative anticoagulant after careful assessment.
The anticoagulant effect declines within 24 hours after the last dose due to the drug’s half-life of about 12 hours. However, residual bleeding risk can persist for up to 48 hours, especially in patients with renal impairment.
For minor dental work, Eliquis is often continued without interruption. For invasive procedures with a high bleeding risk, the dentist may advise temporary cessation of the drug (typically 24-48 hours prior) under guidance from the prescribing physician.
Keep the tablets in their original blister pack or bottle, stored at room temperature away from moisture and direct sunlight. If you need to travel for several weeks, a small portion can be packed in a sealed, airtight container.
Eliquis is approved for non-valvular atrial fibrillation. Patients with mechanical heart valves or moderate-to-severe mitral stenosis require a different anticoagulant (typically warfarin) because DOACs have not been shown to be safe in those settings.
Moderate alcohol intake (up to one standard drink per day for women, two for men) generally does not affect the efficacy of Eliquis. Excessive drinking can increase bleeding risk, so patients are advised to limit alcohol consumption.
Eliquis is the branded product; generic versions of apixaban may be available at a lower price once patent protection expires. Pricing varies by pharmacy and NHS prescribing policies; patients should discuss cost options with their pharmacist or prescriber.
Eliquis is a prescription medication that contains the active ingredient apixaban. It belongs to the class of direct oral anticoagulants (DOACs) and is used to prevent blood clots that can lead to strokes, deep-vein thrombosis (DVT), pulmonary embolism (PE) and other serious conditions. In the United Kingdom, Eliquis is marketed by Bristol-Myers Squibb and Pfizer and is authorized by the Medicines and Healthcare products Regulatory Agency (MHRA) as a prescription-only medicine (POM). The drug is supplied as a pill in two strength options: 2.5 mg and 5 mg tablets.
Apixaban works by directly inhibiting Factor Xa, a key enzyme in the coagulation cascade that converts prothrombin to thrombin. By blocking Factor Xa, apixaban reduces the generation of thrombin, the protein that drives the formation of fibrin clots.
Because apixaban does not require activation by the liver (it is not a pro-drug), its anticoagulant activity is predictable and does not rely on routine laboratory monitoring in most patients.
Eliquis is approved by the MHRA for the following indications:
These uses are supported by large phase III trials such as ARISTOTLE (NVAF) and AMPLIFY (treatment of DVT/PE), which demonstrated that apixaban is at least as effective as warfarin with a lower risk of major bleeding.
Some clinicians prescribe apixaban for situations that are not formally approved in the UK but have been explored in clinical research:
Disclaimer: Off-label use requires individual risk assessment and close monitoring by a qualified healthcare professional.
If any of these serious symptoms occur, seek emergency medical care immediately.
Major interactions (avoid or adjust dose):
Strong CYP3A4/P-gp inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin).
Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin).
Other anticoagulants or antiplatelet agents (warfarin, heparin, clopidogrel) - increase bleeding risk.
Moderate interactions (monitor):
NSAIDs (ibuprofen, naproxen) - may add to gastrointestinal bleeding risk.
SSRIs/SNRIs (fluoxetine, venlafaxine) - can impair platelet function.
Patients should provide a complete medication list, including over-the-counter drugs, supplements and herbal products, to their prescriber.
| Indication | Typical Dose | Frequency | |||| | Stroke prevention in NVAF | 5 mg | Twice daily (morning & evening) | | Treatment of DVT/PE (initial) | 10 mg (5 mg + 5 mg) | Twice daily for 7 days, then 5 mg twice daily | | VTE prophylaxis after hip/knee replacement | 2.5 mg | Twice daily, started 12-24 h post-surgery and continued for 35 days (hip) or 12 days (knee) |
The 2.5 mg strength is used for dose reduction in patients meeting at least two of the following: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL.
If a dose is missed and the next scheduled dose is more than 8 hours away, take the missed tablet as soon as you remember. Do not double the dose to catch up.
Signs of overdose include unusual bruising, bleeding from gums, blood in urine or stool, and severe headache. In the event of suspected overdose, seek urgent medical attention. Activated charcoal may be considered if ingestion was recent; otherwise, supportive care and, if needed, reversal with andexanet alfa (a specific Factor Xa inhibitor reversal agent) is recommended.
Eliquis should not be stopped abruptly without medical advice, especially in patients with atrial fibrillation or recent VTE. A gradual taper is usually unnecessary, but transitioning to another anticoagulant (e.g., warfarin) may require overlap for 48 hours to maintain protection against clotting.
Routine blood-test monitoring of coagulation (e.g., INR) is not required with apixaban. However, periodic assessment may be appropriate in certain circumstances:
Patients should report any new symptoms such as persistent nosebleeds, blood in stool, or unusual bruising.
This article provides educational information about Eliquis (apixaban) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
